External validation of EULAR/ACR classification criteria for idiopathic inflammatory myopathies

We have read with great interest the article published by Jinnin et al., which was an external validation of sensitivity and specificity of the EULAR/ACR (European League Against Rheumatism / American College of Rheumatology) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort. The title and article claim that this is the first external validation study. While this may be true for a Japanese cohort, our intention is to alert the readers to the earlier published validation studies that preceded this and help highlight the complete body of evidence that should be considered.

The idiopathic inflammatory myopathies (IIMs) are a group of uncommon disorders with a potential for significant mortality and morbidity. Progress in the understanding and management of these disorders has been hampered by the lack of validated criteria on which appropriate studies and clinical trials can be based. The classification criteria by the joint European League Against Rheumatism / American College of Rheumatology (EULAR/ACR) consortium1 were developed to address this problem. The criteria were developed from analysis of data collected over 10 years from 976 IIM and 624 non-IIM patients from multiple centres. An important acknowledged limitation was that the external validation did not include controls or comparators and was therefore able to consider sensitivity but not specificity. Further limitations were the low frequency of myositis-specific antibody (MSA) and MRI testing prompting the authors to call for further validation studies.

The report by Jinnin et al2 is therefore a valuable contribution particularly as it addresses a specific population (Japanese), which was minimally represented in the original study. The claim made in the title and body of the report that this is the first external validation study is however incorrect. There are other external validation studies3–7 that precede it and that were on public record prior to the final October 2019 revision date of the report.

Hočevar et al3 and Zhang et al4 had reported their findings in 2018 and May 2019, respectively, and we reported our validation study in Australian patients initially as a preliminary analysis to a study in Australian patients initially as a preliminary analysis to a domestic audience in May 2018.4 The final complete analysis was presented to an international audience at the October 2018 American College of Rheumatology Annual Scientific meeting5 and published in ACR Open Rheumatology online in August 2019.6

We found that in our cohort the EULAR/ACR criteria had very high specificity but lower sensitivity, and lower optimal sensitivity and specificity cut points than that suggested in the EULAR/ACR report. We also explored the effect of MRI and an extended panel of myositis-associated antibodies and MSAs and showed in a logistic regression model that including them as covariates of the EULAR/ACR criteria improved the ability to discriminate between IIM and non-IIM patients.

The confidence with which clinicians may use newly developed classification criteria is determined in part by their validation in other populations and ideally drawing on patients from different geographic locations and ethnicity. Hence validation of the initial EULAR/ACR classification criteria for IIM in an Asian population2 is an important contribution. Our intention here is to alert the readers to the earlier published validation studies that preceded this and help highlight the complete body of evidence that should be considered.

REFERENCES